Related Experiment Video
Updated: May 28, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal
Yukio Ago1, Tatsunori Tanaka, Yuki Kita
1Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan.
Abstract:
Lithium attenuates psychostimulant-induced hyperactivity and behavioral sensitization, but the exact mechanisms are not known. Previous studies show that lithium has neuromodulatory effects on monoamine systems. The present study was aimed to clarify whether prefrontal monoaminergic neurotransmission is involved in the effect of lithium on methamphetamine (METH)-induced behaviors in mice. Lithium attenuated METH-induced hyperactivity and METH-induced increase in extracellular dopamine (DA), but not serotonin (5-HT), levels in the prefrontal cortex. Chronic METH caused behavioral sensitization and enhancement of METH-induced increase in prefrontal 5-HT release (neurochemical sensitization). Co-administration of lithium with METH attenuated behavioral sensitization and neurochemical sensitization. Chronic METH also reduced the 5-HT(1A) receptor agonist osemozotan-induced decrease in prefrontal 5-HT release (desensitization of presynaptic 5-HT(1A) autoreceptor), and this effect was reversed by co-administration of lithium. These results suggest that lithium attenuates acute METH-induced hyperactivity and chronic METH-induced behavioral sensitization via modulation of prefrontal release of DA and 5-HT, respectively. The present study also suggests that a 5-HT(1A) receptor-mediated mechanism is involved in the effect of lithium on chronic METH-induced behavioral sensitization.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Neurochemical Transmission: Sites of Drug Action
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: MAOIs and Other Agents
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

